CTOs on the Move

Proteolix

www.proteolix.com

 
Proteolix, Inc. is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.proteolix.com
  • 333 Allerton Ave
    South San Francisco, CA USA 94080
  • Phone: 650.266.2600

Executives

Name Title Contact Details

Similar Companies

XtalPi

XtalPi is a pharmaceutical technology company that is reinventing the industry’s approach to drug research and development with its Intelligent Digital Drug Discovery and Development (ID4) platform.

Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and discovery capabilities.

MethylGene

MethylGene Inc. is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DepoMed

Depomed is a leading specialty pharmaceutical company committed to putting the Patient First in everything we do; with a focus on enhancing the lives of patients, families, physicians, providers and in payors through commercialization of products in the areas of pain and neurology, and developing drugs in areas of unmet medical needs. Depomed currently markets three medicines focused on neuropathic pain and migraine through its Neurology and Pain Business and has an emerging Specialty Business focused on orphan drug indications and areas of unmet medical need. Depomed has a clear THREE PILLAR strategy for growth: MAINTAIN a strong/profitable NUCYNTA franchise through a commercialization agreement with Collegium, GROW the Neurology and Pain Business and BUILD a new Specialty Business through a recent Cosyntropin transaction. The company`s strategy is to continue to identify, license and develop new products-that offer enhanced therapeutic options to patient populations that may be underserved by existing therapies. As part of the transformation strategy, Depomed will be relocating its headquarters out of California. Information about location will be shared during the interview process. Depomed is listed on the NASDAQ market under the ticker DEPO. Depomed is an AA/EEO/Veterans/Disabled employer.

Oxford Finance Corporation

Oxford Finance Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.